Report Sections

See All Reports

  • HP:0001297: Stroke
  • Pneumonia (361) Abnormality of the cardiovascular system (36) Respiratory tract infection (36) Neoplasm (29) Hypoxemia (28) Diabetes mellitus (25) Depressivity (24) Thromboembolism (23) Acute kidney injury (22) Abnormal lung morphology (21) Anosmia (19) Hypertension (18) Abnormality of coagulation (15) Pulmonary embolism (15) Pulmonary fibrosis (15) Stroke (14) Arthritis (14) Interstitial pneumonitis (14) Myocardial infarction (12) Type II diabetes mellitus (12) Deep venous thrombosis (11) Rheumatoid arthritis (10) Leukemia (10) Respiratory distress (10) Low levels of vitamin D (10) Behavioral abnormality (9) Mental deterioration (9) Chronic pain (9) Congestive heart failure (8) Myocarditis (8) Type I diabetes mellitus (8) Sepsis (8) Infertility (7) Abnormality of the liver (7) Lymphopenia (7) Inflammation of the large intestine (7) Pulmonary obstruction (7) Pulmonary insufficiency (7) Immunodeficiency (6) Systemic lupus erythematosus (6) Chronic pulmonary obstruction (6) Abnormality of the gastrointestinal tract (6) Neoplasm of the lung (6) Encephalopathy (5) Obesity (5) Lymphoma (5) Autoimmunity (5) Breast carcinoma (5) Disseminated intravascular coagulation (5) Fatigue (5) Abnormality of the kidney (4) Coronary artery atherosclerosis (4) Cardiac arrest (4) Headache (4) Colon cancer (4) Arrhythmia (4) Carcinoma (4) Hypercoagulability (4) Autistic behavior (3) Seizure (3) Cardiomyopathy (3) Dysphagia (3) Migraine (3) Pulmonary arterial hypertension (3) Asthma (3) Bronchiectasis (3) Neoplasm of the pancreas (3) Psoriasiform dermatitis (3) Attention deficit hyperactivity disorder (3) Cutaneous melanoma (3) Neoplasm of head and neck (3) Pulmonary edema (3) Insomnia (3) Neoplasm of the large intestine (3) Renal insufficiency (2) Hypogeusia (2) Hearing impairment (2) Abnormality of the eye (2) Visual impairment (2) Conjunctivitis (2) Psychosis (2) Autism (2) Dementia (2) Abnormality of the endocrine system (2) Abnormality of the thyroid gland (2) Jaundice (2) Hepatic fibrosis (2) Premature birth (2) Abnormal heart morphology (2) Abnormality of blood and blood-forming tissues (2) Fever (2) Diarrhea (2) Hypothermia (2) Neurodegeneration (2) Abnormal intestine morphology (2) Alopecia of scalp (2) Encephalitis (2) Obstructive sleep apnea (2) Male infertility (2) Stillbirth (2) Paroxysmal atrial fibrillation (2) Lymphoid leukemia (2) Myeloproliferative disorder (2) Chronic lymphatic leukemia (2) Renal cell carcinoma (2) Multiple myeloma (2) Abnormal anterior horn cell morphology (2) Amyotrophic lateral sclerosis (2) Sleep apnea (2) Cystoid macular edema (2) Hemeralopia (2) Arteritis (2) Chronic kidney disease (2) Cervix cancer (2) Cholangitis (2) Cholangiocarcinoma (2) Myositis (2) Neuroendocrine neoplasm (2) Neoplasm of the rectum (2) Mania (2) Nephritis (1) Menorrhagia (1) Conductive hearing impairment (1) Cataract (1) Amblyopia (1) Periodontitis (1) Abnormality of the nervous system (1) Oligospermia (1) Adrenal insufficiency (1) Hyperaldosteronism (1) Abnormality of the skin (1) Lymphedema (1) Cholecystitis (1) Keratoconjunctivitis (1) Intellectual disability (1) Spastic diplegia (1) Hemiparesis (1) Meningitis (1) Cerebral hemorrhage (1) Abnormal joint morphology (1) Hepatic failure (1) Hepatocellular carcinoma (1) Intrauterine growth retardation (1) Hoarse voice (1) Dysphonia (1) Weak voice (1) Sudden cardiac death (1) Cor pulmonale (1) Tachycardia (1) Aortic valve stenosis (1) Bradycardia (1) Torsade de pointes (1) Atrioventricular block (1) Angina pectoris (1) Pancreatitis (1) Premature rupture of membranes (1) Weight loss (1) Thrombocytopenia (1) Autoimmune thrombocytopenia (1) Gastroesophageal reflux (1) Anorexia (1) Esophageal varix (1) Apnea (1) Status epilepticus (1) Subarachnoid hemorrhage (1) Memory impairment (1) Difficulty walking (1) Hyperkinetic movements (1) Alzheimer disease (1) Increased intracranial pressure (1) Colitis (1) Biliary cirrhosis (1) Hypotension (1) Vascular dilatation (1) Atherosclerosis (1) Osteoarthritis (1) Tachypnea (1) Hypoventilation (1) Myelodysplasia (1) Neoplasm of the liver (1) Hypokalemia (1) Hyponatremia (1) Hyperphosphatemia (1) Reduced factor VIII activity (1) Skeletal muscle atrophy (1) Myalgia (1) Muscular dystrophy (1) Neonatal death (1) Increased body weight (1) Neoplasm of the nervous system (1) Malnutrition (1) Thrombophlebitis (1) Ventricular tachycardia (1) Acute myeloid leukemia (1) Dilatation of the cerebral artery (1) Knee osteoarthritis (1) Monoclonal immunoglobulin M proteinemia (1) Intraalveolar phospholipid accumulation (1) Neoplasm of the stomach (1) Neoplasm of the genitourinary tract (1) Neoplasm of the skin (1) Female infertility (1) Benign prostatic hyperplasia (1) Hip osteoarthritis (1) Renal neoplasm (1) Uterine neoplasm (1) Testicular neoplasm (1) Intestinal atresia (1) Tonsillitis (1) Inflammatory abnormality of the skin (1) Placental abruption (1) Postprandial hyperglycemia (1) Endometrial carcinoma (1) Erythroid hypoplasia (1) Asterixis (1) Glioblastoma multiforme (1) B-cell lymphoma (1) Ciliary dyskinesia (1) Morphea (1) Allergy (1) Non-Hodgkin lymphoma (1) Retinal vein occlusion (1) Heart block (1) Dyspareunia (1) Ductal carcinoma in situ (1) Endometriosis (1) Cardiogenic shock (1) Vulvar neoplasm (1) Addictive behavior (1) Femur fracture (1) Neonatal sepsis (1) Glue ear (1) Neoplasm of the central nervous system (1) Abnormality of movement (1) Ulcerative colitis (1) Crohn's disease (1) Endocarditis (1) Toxemia of pregnancy (1) Neoplasm of the larynx (1) Ovarian neoplasm (1) Vaginal neoplasm (1) Cellulitis (1) Bulimia (1) Atelectasis (1) Esophageal neoplasm (1) Lymphocytosis (1) Polymenorrhea (1)

    HP:0001297: Stroke

    Developed by Shray Alag, The Harker School
    Sections: Correlations, Clinical Trials, and HPO

    Correlations computed by analyzing all clinical trials.

    Navigate: Clinical Trials and HPO


    Correlated Drug Terms (20)


    Name (Synonyms) Correlation
    drug626 COVID-19 swap test PCR Wiki 0.27
    drug3778 exposure Wiki 0.27
    drug805 Collection of odour samples Wiki 0.27
    Name (Synonyms) Correlation
    drug3200 Sulfur hexafluoride lipid-type A microspheres Wiki 0.27
    drug2004 MindRhythm Harmony Wiki 0.27
    drug2840 Robotic therapy Wiki 0.27
    drug2777 Rehabilitation exercise protocol Wiki 0.27
    drug1939 Mechanical Trombectomy Wiki 0.27
    drug461 Blood collection Wiki 0.27
    drug608 COVID-19 barrier box Wiki 0.27
    drug770 Clinical interview Wiki 0.27
    drug1274 Fenofibrate Wiki 0.27
    drug2444 Pioglitazone 45 mg Wiki 0.27
    drug3684 autopsy Wiki 0.27
    drug3505 Usual care Wiki 0.15
    drug2237 Observation Wiki 0.13
    drug415 Best Practice Wiki 0.12
    drug2951 Saliva collection Wiki 0.11
    drug3375 Tocilizumab Wiki 0.04
    drug2448 Placebo Wiki 0.01

    Correlated MeSH Terms (33)


    Name (Synonyms) Correlation
    D020521 Stroke NIH 1.00
    D013226 Status Epilepticus NIH 0.27
    D002543 Cerebral Hemorrhage NIH 0.27
    Name (Synonyms) Correlation
    D003072 Cognition Disorders NIH 0.27
    D013345 Subarachnoid Hemorrhage NIH 0.27
    D016757 Death, Sudden, Cardiac NIH 0.27
    D013610 Tachycardia NIH 0.27
    D017180 Tachycardia, Ventricular NIH 0.27
    D004827 Epilepsy NIH 0.27
    D007238 Infarction NIH 0.19
    D000070642 Brain Injuries, Traumatic NIH 0.19
    D012640 Seizures NIH 0.19
    D009203 Myocardial Ischemia NIH 0.15
    D007511 Ischemia NIH 0.15
    D006470 Hemorrhage NIH 0.15
    D003643 Death, NIH 0.13
    D009422 Nervous System Diseases NIH 0.13
    D003324 Coronary Artery Disease NIH 0.13
    D001930 Brain Injuries, NIH 0.12
    D007676 Kidney Failure, Chronic NIH 0.12
    D029424 Pulmonary Disease, Chronic Obstructive NIH 0.11
    D010300 Parkinsonian NIH 0.11
    D008173 Lung Diseases, Obstructive NIH 0.10
    D060825 Cognitive Dysfunction NIH 0.09
    D003866 Depressive Disorder NIH 0.05
    D004194 Disease NIH 0.05
    D014947 Wounds and Injuries NIH 0.05
    D009369 Neoplasms, NIH 0.05
    D001008 Anxiety Disorders NIH 0.04
    D003863 Depression, NIH 0.03
    D007239 Infection NIH 0.01
    D045169 Severe Acute Respiratory Syndrome NIH 0.01
    D018352 Coronavirus Infections NIH 0.01

    Correlated HPO Terms (14)


    Name (Synonyms) Correlation
    HP:0002133 Status epilepticus HPO 0.27
    HP:0001649 Tachycardia HPO 0.27
    HP:0002138 Subarachnoid hemorrhage HPO 0.27
    Name (Synonyms) Correlation
    HP:0001342 Cerebral hemorrhage HPO 0.27
    HP:0004756 Ventricular tachycardia HPO 0.27
    HP:0001645 Sudden cardiac death HPO 0.27
    HP:0001658 Myocardial infarction HPO 0.15
    HP:0001250 Seizure HPO 0.15
    HP:0001677 Coronary artery atherosclerosis HPO 0.13
    HP:0006510 Chronic pulmonary obstruction HPO 0.11
    HP:0006536 Pulmonary obstruction HPO 0.10
    HP:0001268 Mental deterioration HPO 0.09
    HP:0000716 Depressivity HPO 0.05
    HP:0002664 Neoplasm HPO 0.05

    Clinical Trials

    Navigate: Correlations   HPO

    There are 14 clinical trials


    1 Tociluzumab for Cytokine Release Syndrome With SARS-CoV-2: An Open-Labeled, Randomized Phase 3 Trial

    This phase III trial compares the effect of adding tocilizumab to standard of care versus standard of care alone in treating cytokine release syndrome (CRS) in patients with SARS-CoV-2 infection. CRS is a potentially serious disorder caused by the release of an excessive amount of substance that is made by cells of the immune system (cytokines) as a response to viral infection. Tocilizumab is used to decrease the body's immune response. Adding tocilizumab to standard of care may work better in treating CRS in patients with SARS-CoV-2 infection compared to standard of care alone.

    NCT04361552
    Conditions
    1. Cerebrovascular Accident
    2. Chronic Obstructive Pulmonary Disease
    3. Chronic Renal Failure
    4. Coronary Artery Disease
    5. Diabetes Mellitus
    6. Malignant Neoplasm
    7. SARS Coronavirus 2 Infection
    Interventions
    1. Other: Best Practice
    2. Biological: Tocilizumab
    MeSH:Infection Neoplasms Lung Diseases, Obstructive Pulmonary Disease, Chronic Obstructive Stroke Kidney Failure, Chronic Coronary Artery Disease
    HPO:Chronic pulmonary obstruction Coronary artery atherosclerosis Neoplasm Pulmonary obstruction Stroke

    Primary Outcomes

    Description: The 7-day length of invasive MV for each arm will be estimated with 95% confidence intervals (CIs) using the exact binomial distribution. Their difference by the arms will be tested by Cochran-Mantel-Haenszel (CMH) test stratified by the age group and Sequential Organ Failure Assessment (SOFA) score at significance level of 0.05.

    Measure: 7-day length of invasive mechanical ventilation (MV)

    Time: Up to 7 days

    Description: Defined as death within 30-day after randomization. The 30-day mortality rate for each arm will be estimated with 95% CIs using the exact binomial distribution. Their difference by the arms will be tested CMH test stratified by the age group and SOFA score at significance level of 0.05.

    Measure: 30-day mortality rate

    Time: Up to 30-day after randomization

    Secondary Outcomes

    Description: The rate of ICU transfer for each arm will be estimated with 95% CIs using the exact binomial distribution. Their difference by the arms will be tested CMH test stratified by the age group and SOFA score at significance level of 0.05.

    Measure: Rate of intensive care (ICU) transfer

    Time: Up to 2 years

    Description: The rate of invasive mechanical ventilation for each arm will be estimated with 95% CIs using the exact binomial distribution. Their difference by the arms will be tested CMH test stratified by the age group and SOFA score at significance level of 0.05.

    Measure: Rate of invasive mechanical ventilation

    Time: Up to 2 years

    Description: The rate of tracheostomy for each arm will be estimated with 95% CIs using the exact binomial distribution. Their difference by the arms will be tested CMH test stratified by the age group and SOFA score at significance level of 0.05.

    Measure: Rate of tracheostomy

    Time: Up to 2 years

    Description: Will first be described by median and inter-quartile, and then compared between two arms by Wilcoxon Sum-Rank test

    Measure: Length of ICU stay

    Time: Up to 2 years

    Measure: Length of hospital stay

    Time: Up 2 years
    2 Acute Cardiovascular Events Triggered by COVID-19-Related, Non-infectious Stress The Jordan COVID-9 caRdiovascular Events (JoCORE) Study

    The current COVID19 pandemic has afflicted almost the whole globe. The stress related to the pandemic, not the direct virus-related injury, can be potentially associated with acute cardiovascular events due to a large list of physical and psychosocial stresses. This study is a cross sectional study that will enroll patients evaluated during the COVID19 pandemic period for acute cardiovascular events.

    NCT04368637
    Conditions
    1. Acute Myocardial Infarction
    2. Ventricular Tachycardia
    3. Sudden Cardiac Death
    4. Stroke, Acute
    MeSH:Stroke Myocardial Infarction Tachycardia Tachycardia, Ventricular Death, Sudden, Cardiac Infarction Death
    HPO:Myocardial infarction Stroke Sudden cardiac death Tachycardia Ventricular tachycardia

    Primary Outcomes

    Description: Acute myocardial infarction as diagnosed by ST segment elevation or depression or inverted T wave on 12-lead EKG and elevated levels of cardiac troponins above the 99% of the normal values. A. Acute MI (STEMI and NSTEMI). B. Aborted on non-aborted sudden cardiac death not attributed to a known etiology. C. Sustained or non-sustained ventricular tachy-arrhythmia not attributed to a known etiology. D. ICD shocks. 3. Absence of suspected or confirmed infection with the COVID19 virus. 4. Definite physical or psycho-social stressful trigger appearing in relation to the COVID-19 situation (lock down stress, financial stress, anger, depression, fear, sorrow, death of a significant person, eating binges, smoking binges, physical stress [carrying walking for shopping and carrying excess weights] ..etc) as judged by a unanimous agreement of three investigators in the steering committee.

    Measure: Acute cardiovascular event triggered by COVID-19 stress

    Time: 4 months

    Description: Typical ventricular tachycardia on 12-lead EKG or EKG monitor.

    Measure: Ventricular tachycardia

    Time: 4 months

    Description: acute neurological symptoms of hemiparesis or dysrthria due to brain ischemia proven by computerized tomography or magnatic resonance

    Measure: acute stroke

    Time: 4 months

    Description: Finding an episode of ventricular tachycardia on interrogation of ICD tracing

    Measure: Implantable cardioverter defibrillator (ICD) shock

    Time: 4 months
    3 Impact of th Covid-19 Epidemic on Acute Stroke Management

    The Covid-19 pandemic is a pandemic of an emerging infectious disease, coronavirus 2019 (Covid-19), caused by the coronavirus SARS-CoV-2. It appears in November 2019 in the city of Wuhan, China, and spreads worldwide from February 2020. The first cases of infection in France were confirmed on 24 January 2020. As of April 14, 103,573 cases of infection were confirmed, 32,292 hospitalized cases, including 6,730 in intensive care, with 15,729 deaths recorded1. The most affected regions are Ile de France and the Grand Est (in particular the Haut-Rhin department). Containment of the entire French population was introduced on 17 March, with the aim of reducing the spread of the virus and relieving the burden on the health system, particularly the intensive care units. This unprecedented health crisis, as well as the social containment measures in themselves, has repercussions on other acute medical pthologies, not directly related to the viral infection. It appears that the number of patients treated for acute stroke has suddenly declined since the beginning of the epidemic. However, it is not clear whether it is the incidence of stroke that has declined or simply the proportion of patients presenting within the time frame that allows for treatment in the acute phase (by thrombolysis or thrombectomy).

    NCT04370197
    Conditions
    1. Stroke, Acute
    MeSH:Stroke
    HPO:Stroke

    Primary Outcomes

    Measure: Study of the effect of pandemic covid-19 on the management of stroke patients

    Time: 1 month
    4 Stroke Rehabilitation Outcome During COVID-19 Lockdown

    COVID-19 has a big impact on individuals and society as a whole. Especially persons with (multiple) comorbidities such as stroke are affected. The impact of COVID-19 on stroke rehabilitation delivery and stroke patients' functioning is unclear.

    NCT04373109
    Conditions
    1. Stroke
    2. Rehabilitation
    3. COVID-19
    4. Cohort Studies
    Interventions
    1. Behavioral: Observation
    MeSH:Stroke
    HPO:Stroke

    Primary Outcomes

    Description: Nature of rehabilitation therapy, and number and duration of rehabilitation therapy sessions

    Measure: Rehabilitation data

    Time: 3 month after start lockdown

    Description: Patient-reported upper limb use in daily life

    Measure: Motor Activity Log - 14 Item Version

    Time: 3 month after start lockdown

    Description: Patient-reported engagement in physical activity in daily life

    Measure: International Physical Activity Questionnaire

    Time: 3 month after start lockdown

    Description: Patient-self-assessment comprising the following categories: 1) physical function, 2) anxiety, 3) depression, 4) fatigue, 5) sleep disturbance, 6) ability to participate in social roles and activities, 7) pain interference and 8) pain intensity

    Measure: Patient-Reported Outcomes Measurement Information System - 29 Version

    Time: 3 month after start lockdown

    Secondary Outcomes

    Description: Patient-reported global rating of physical activity engagement and upper limb use in daily life

    Measure: Global Rating of Perceived Changes (physical activity engagement and upper limb use)

    Time: 4 weeks after lockdown ("extraordinary situation" as defined by the Swiss law), 3 months after lockdown, 6 months after lockdown

    Description: Self-reported questionnaire regarding severity of fatigue and its influence on the performance of daily life activities

    Measure: Fatigue Severity Scale

    Time: 4 weeks after lockdown ("extraordinary situation" as defined by the Swiss law), 3 months after lockdown, 6 months after lockdown

    Description: Depression and anxiety

    Measure: Hospital Anxiety and Depression Scale

    Time: 4 weeks after lockdown ("extraordinary situation" as defined by the Swiss law), 3 months after lockdown, 6 months after lockdown

    Description: Assesses cognitive functions

    Measure: Montreal Cognitive Assessment

    Time: 4 weeks after lockdown ("extraordinary situation" as defined by the Swiss law), 3 months after lockdown, 6 months after lockdown

    Description: Classification regarding the ability to walk independently, with or without a walking aid and takes the type of walking surface into account

    Measure: Functional Ambulation Categories

    Time: 4 weeks after lockdown ("extraordinary situation" as defined by the Swiss law), 3 months after lockdown, 6 months after lockdown

    Description: Gait speed and cadence

    Measure: Ten-Meter Walk Test

    Time: 4 weeks after lockdown ("extraordinary situation" as defined by the Swiss law), 3 months after lockdown, 6 months after lockdown

    Description: Measures the ability of patients to make postural adjustments (e.g, move in bed), transfer (e.g. be-tween bed to chair), walk, and use stairs

    Measure: Rivermead Mobility Index

    Time: 4 weeks after lockdown ("extraordinary situation" as defined by the Swiss law), 3 months after lockdown, 6 months after lockdown

    Description: Self-reported measure in which patients rate how confident they are in maintaining balance when performing 16 daily life tasks

    Measure: Activities-specific Balance Confidence Scale

    Time: 4 weeks after lockdown ("extraordinary situation" as defined by the Swiss law), 3 months after lockdown, 6 months after lockdown

    Description: Upper and lower limb motor function

    Measure: Fugl-Meyer Motor Assessment

    Time: 4 weeks after lockdown ("extraordinary situation" as defined by the Swiss law), 3 months after lockdown, 6 months after lockdown

    Description: Upper limb capacity

    Measure: Action Research Arm Test

    Time: 4 weeks after lockdown ("extraordinary situation" as defined by the Swiss law), 3 months after lockdown, 6 months after lockdown

    Description: Global disability

    Measure: modified Rankin Scale

    Time: 4 weeks after lockdown ("extraordinary situation" as defined by the Swiss law), 3 months after lockdown, 6 months after lockdown

    Description: Neurological impairments

    Measure: National Institutes of Health Stroke Scale

    Time: 4 weeks after lockdown ("extraordinary situation" as defined by the Swiss law), 3 months after lockdown, 6 months after lockdown

    Description: Nature of rehabilitation therapy, and number and duration of rehabilitation therapy sessions

    Measure: Rehabilitation data

    Time: 4 weeks after lockdown ("extraordinary situation" as defined by the Swiss law), 6 months after lockdown

    Description: Patient-reported upper limb use in daily life

    Measure: Motor Activity Log - 14 Item Version

    Time: 4 weeks after lockdown ("extraordinary situation" as defined by the Swiss law), 6 months after lockdown

    Description: Patient-reported engagement in physical activity in daily life

    Measure: International Physical Activity Questionnaire

    Time: 4 weeks after lockdown ("extraordinary situation" as defined by the Swiss law), 6 months after lockdown

    Description: Patient-self-assessment comprising the following categories: 1) physical function, 2) anxiety, 3) depression, 4) fatigue, 5) sleep disturbance, 6) ability to participate in social roles and activities, 7) pain interference and 8) pain intensity

    Measure: Patient-Reported Outcomes Measurement Information System - 29 Version

    Time: 4 weeks after lockdown ("extraordinary situation" as defined by the Swiss law), 6 months after lockdown
    5 COVID-19 Prevalence, Morbidity and Long Term Cognitive Deficits in Consecutive Patients Presenting With Acute Neurological Symptoms

    The purpose is to investigate the COVID-19 prevalence, associated morbidity and long-term cognitive deficits in consecutive patients presenting with acute neurological symptoms

    NCT04377425
    Conditions
    1. Neurological Diseases or Conditions
    2. Stroke, Acute
    3. Seizure Disorder
    Interventions
    1. Diagnostic Test: COVID-19 swap test PCR
    MeSH:Stroke Seizures Nervous System Diseases Epilepsy Cognition Disorders Cognitive Dysfunction
    HPO:Bilateral tonic-clonic seizure Cognitive impairment Focal sensory seizure Focal-onset seizure Generalized-onset seizure Mental deterioration Seizure Stroke

    Primary Outcomes

    Description: To investigate the prevalence of COVID-19 infections in consecutive patients with acute onset of neurological symptoms (with or without prior neurological disease)

    Measure: Prevalence of COVID-19 infection in consecutive patients with neurological symptoms

    Time: 6 months

    Secondary Outcomes

    Description: Three months cognitive function (Montreal Cognitive Assessment) of COVID-19 positive patients compared to COVID-19 negative patients

    Measure: Three months cognitive function of COVID-19 positive patients

    Time: 3 months

    Description: Characterization of the neurological symptoms in neurological COVID-19 positive patients (exploratory endpoint)

    Measure: Clinical presentation of neurological symptoms in COVID-19 positive patients

    Time: 6 months

    Description: Prevalence of pre-symptomatic and asymptomatic COVID-19pos in acutely admitted patients with a primary complaint of neurological symptoms.

    Measure: Prevalence of pre- and asymptomatic COVID-19 positive patients in acutely admitted neurological patients

    Time: 6 months

    Description: Prevalence of anosmia in COVID-19pos patients compared to COVID-19neg patients

    Measure: Anosmia in COVID-19 positive patients

    Time: 6 months

    Description: Neuro-specific and inflammatory blood- and cerebrospinal fluid markers in COVID-19 positive patients compared to COVID-19 negative matched controls

    Measure: Exploratory analysis on neuro-specific and inflammatory blood and cerebrospinal fluid markers of COVID-19 infection

    Time: 24 months

    Description: Functional and immunologic plasma assays will be employed to analyze proteins and pathways in coagulation and fibrinolysis

    Measure: Exploratory analysis of the coagulation profile of COVID-19 positive patients compared to COVID-19neg patients

    Time: 24 months
    6 Upper Limb Robotic Rehabilitation in Stroke Survivors Using a Portable Device During the COVID-19 Outbreak. A Feasibility Study

    The COVID-19 outbreak requires a rapid re-shaping of the entire organization of the rehabilitation services. This includes the design and planning of appropriate rehabilitation settings, intervention and logistics for organizing space for patients. The aims of this study are: (a) to evaluate the feasibility of the bedside use of a novel rehabilitation device for upper limb in patients with stroke; (b) to evaluate the motor and cognitive outcomes of the treatment; (c) to validate the instrumental outcomes provided by the device.

    NCT04392453
    Conditions
    1. Stroke
    Interventions
    1. Device: Robotic therapy
    MeSH:Stroke
    HPO:Stroke

    Primary Outcomes

    Description: It is a tool for measuring the usability

    Measure: System Usability Scale (SUS)

    Time: After 30 rehabilitation sessions

    Description: It is a tool for measuring the acceptability.

    Measure: Technology Acceptance Model (TAM)

    Time: After 30 rehabilitation sessions

    Description: It is a tool for measuring the satisfaction.

    Measure: Likert Scale

    Time: After 30 rehabilitation sessions

    Secondary Outcomes

    Description: The Fugl-Meyer Assessment is a stroke-specific, performance-based impairment index. It is designed to assess motor functioning, sensation and joint functioning in patients with post-stroke hemiplegia. It is applied clinically and in research to determine disease severity, describe motor recovery, and to plan and assess treatment.

    Measure: Fugl-Meyer Assessment for upper extremity (FMA-UE)

    Time: At baseline; after 30 rehabilitation sessions

    Description: It is a clinical instrument for characterizing the strength of the paretic upper extremity following stroke.

    Measure: Motricity Index for the upper extremity (MI-UE)

    Time: At baseline; after 30 rehabilitation sessions

    Description: It is a clinical instrument for characterizing upper limb spasticity. Shoulder, elbow and wrist spasticity will be assessed.

    Measure: Modified Ashworth Scale (MAS)

    Time: At baseline; after 30 session rehabilitation sessions

    Description: It is a unidimensional measure of pain intensity in adults.

    Measure: Numeric Pain Rating Scale (NPRS)

    Time: At baseline; after 30 rehabilitation sessions

    Description: It is a measure of independence in activities of daily living.

    Measure: Modified Barthel Index (mBI)

    Time: At baseline; after 30 rehabilitation sessions

    Description: It is a widely used screening assessment for detecting cognitive impairment.

    Measure: Montreal Cognitive Assessment (MoCA)

    Time: At baseline; after 30 rehabilitation sessions

    Description: The kinematics of the end-effector of the robot will be acquired during point-to-point tasks.

    Measure: Kinematic parameters

    Time: At baseline (twice, one day apart); after 10 rehabilitation sessions; after 20 rehabilitation sessions; after 30 rehabilitation sessions
    7 Endovascular Thrombectomy in COVID-19 Infected Patients: Intrahospital and Peri-operative Outcomes

    About 5% of COVID-19 patients may present symptoms related to acute ischemic stroke (AIS). Treatment-management and outcomes related to mechanical thrombectomy (MT) for COVID-19 infected patients harboring large vessel occlusion is largely unknown. This multicentric study aims to investigate morbidity, mortality and neurological outcomes after MT performed in patients with COVID-19 infection.

    NCT04406090
    Conditions
    1. Ischemic Stroke
    2. Covid 19
    Interventions
    1. Other: Mechanical Trombectomy
    MeSH:Stroke Ischemia
    HPO:Stroke

    Primary Outcomes

    Description: Intrahospital mortality after MT for COVID-19 infected patients harboring large vessel occlusion

    Measure: Intrahospital mortality

    Time: 1day

    Description: short-term morbidity after MT for COVID-19 infected patients harboring large vessel occlusion

    Measure: short-term morbidity

    Time: 1 day

    Secondary Outcomes

    Description: Angiographic success after MT for COVID-19 infected patients harboring large vessel occlusion

    Measure: Angiographic success

    Time: 1 day
    8 EPISODE-PS-COVID: hEad Pulse for Ischemic StrOke DEtection Prehospital Study During the COVID-19 Pandemic

    Prehospital providers encounter patients with suspected stroke frequently. Stroke and COVID-19 are related potentially putting these healthcare workers at risk of COVID-19 infection. In addition, prehospital providers need tools to help triage large vessel stroke patients to comprehensive stroke centers.

    NCT04445493
    Conditions
    1. Stroke, Acute
    2. COVID-19
    Interventions
    1. Device: MindRhythm Harmony
    MeSH:Stroke
    HPO:Stroke

    Primary Outcomes

    Measure: Prevalence of COVID-19 infection in suspected stroke population

    Time: Through Study Completion, an average of 6 months

    Description: Proportion of head pulse studies deemed of high quality for further analysis

    Measure: Quality head pulse recordings

    Time: Through Study Completion, an average 6 months
    9 Physiotherapy as a Complimentary Treatment in Reducing Viral-Load, Complications, Death, Expedite Discharge and Improve Quality of Life, Exercise Endurance and Capacity in Stroke Survivors With CoViD-19: A Clinical-Controlled Study

    Background: Coronavirus (CoViD-19) positive stroke survivors (SSv) with comorbidities faces possibility for mortality. Study reports success of physiotherapy in CoViD-19 positive SSv with multiple comorbidities. Methods: This clinical controlled study involve a minimum of 30 SSv and 30 age and sex-matched non-stroke individuals with multiple comorbidities with CoViD-19 status confirmed using Real-Time Quantitative-Polymerase Chain Reaction. The Cycle Threshold (CT) and nucleic acid content in the test sample (NA) will be recorded from the virology test results. Their exercise endurance, exercise capacities and quality of life will be assessed using 3-minutes' walk test and 3-meters test and Stroke Specific Quality of Life Questionnaire. Measurements will be taken at every three days intervals from admission to discharge from hospital-isolation. They will receive their normal treatments for CoViD-19 in addition to daily Physiotherapy for the SSv delivered through E-Platform. the Zoom and the WhatsApp video platforms will be used for the interactions between the physiotherapists and the participants. A pre-tested exercise protocol for stroke patients developed by the Stroke and Nervous System Disorders research group of the University of Lagos, Nigeria will be used for the E-exercises. The exercise package will be loaded into the phones of the participants at hospital admission. The Physiotherapists will lead in the exercises through video interaction will the participants watches the video programme. Their risks for respiratory complications (RC), ventilation (RV) and death (RD) will be analysed. Data will be analysed using independent t-test, Analysis of Co-Variance, and multivariate retrogression, survival analyses, Friedman Analysis of Variance and MannWithney U test (95% Confident Interval). Anticipated Outcomes: It is anticipated that the outcome of this study will provide evidence for inclusion of Physiotherapy in the acute management of individuals tested positive for CoViD-19 most important for the stroke survivors tested positive for CoViD-19 at acute stage to reduce the odds of developing complications expedite discharge and reduce odd of death.

    NCT04471831
    Conditions
    1. Corona Virus Infection
    2. Stroke
    Interventions
    1. Other: Rehabilitation exercise protocol
    MeSH:Coronavirus Infections Severe Acute Respiratory Syndrome Stroke
    HPO:Stroke

    Primary Outcomes

    Description: The CT value of a reaction is defined as the cycle number when the fluorescence of a PCR product can be detected above the background signal. The CT value is associated with the amount of PCR product in the reaction. The lower the CT value, the more PCR product that is present. It does not have unit of measurement

    Measure: Cycle Threshold (CT) values as recorded from the series of the qRT-PCR

    Time: From date of admission until the date of discharge from the isolation ward or date of death, whichever came first, assessed up to 18 months. Length of hospital stay before discharge/death will be documented

    Description: This is the inverse of the Cycle Threshold. It does not have unit of measurement.

    Measure: Nucleic acid values as calculated from the Cycle Threshold recorded from the series of the qRT-PCR

    Time: From date of admission until the date of discharge from the isolation ward or date of death, whichever came first, assessed up to 18 months. Length of hospital stay before discharge/death will be documented

    Description: Perceived life experience by the participants in relation to the present situation. It does not have unit of measurement.

    Measure: Quality of Life perception

    Time: From date of admission until the date of discharge from the isolation ward or date of death, whichever came first, assessed up to 18 months. Length of hospital stay before discharge/death will be documented

    Description: The maximum amount of physical exertion that a patient can sustain. It will be tested using the 3-metre walk test. This is the time taken to complete a 3-metre distance. The unit of measurement is in seconds

    Measure: Exercise capacity

    Time: From date of admission until the date of discharge from the isolation ward or date of death, whichever came first, assessed up to 18 months. Length of hospital stay before discharge/death will be documented

    Description: The maximum length a patient can sustain an exercise procedure, It will be tested using the 3-minutes' walk test This is the distance covered within a 3-minute walk. The unit of measurement is in metres

    Measure: Exercise endurance

    Time: From date of admission until the date of discharge from the isolation ward or date of death, whichever came first, assessed up to 18 months. Length of hospital stay before discharge/death will be documented
    10 Severe Neurologic Injury Outcomes During COVID-19 Crisis

    A prospective cohort minimal risk study to determine the impact of the COVID-19 crisis on outcomes of neurologically injured ICU patients.

    NCT04496076
    Conditions
    1. Sars-CoV2
    2. Severe Neurologic Injury
    3. Ischemic Stroke
    4. Hemorrhagic Stroke
    5. Intracerebral Hemorrhage
    6. Subarachnoid Hemorrhage
    7. Traumatic Brain Injury
    8. Status Epilepticus
    MeSH:Stroke Brain Injuries Brain Injuries, Traumatic Subarachnoid Hemorrhage Cerebral Hemorrhage Status Epilepticus Hemorrhage Wounds and Injuries
    HPO:Cerebral hemorrhage Status epilepticus Stroke Subarachnoid hemorrhage

    Primary Outcomes

    Measure: In-hospital Mortality

    Time: At hospital discharge, approximately 1 month

    Measure: 30-day mortality

    Time: 30 days post-hospital discharge

    Secondary Outcomes

    Description: Care treatment such as ventilator use, intubation, and/or tracheostomy

    Measure: Limitations of patient care- Frequency of care not being provided

    Time: During In-hospital course, up to 1 month

    Measure: Limitations of patient care- Conversion of DNR/DNI/CMO status

    Time: During In-hospital course, up to 1 month
    11 Consequences of the COVID-19 Lockdown on Health and Well-being of Patients With Parkinson Disease and Post-stroke

    The study aimed at describing the effects of the COVID-19 social distancing on function, health and well-being of patients with Parkinson's disease or post-stroke, and test the association between the patient activation level and these effects.An anonymous survey was distributed through social media and patient associations.Community-living patients with Parkinson's disease or post-stroke were invited to answer the survey.

    NCT04535297
    Conditions
    1. Parkinson Disease
    2. Stroke
    Interventions
    1. Other: exposure
    MeSH:Stroke Parkinson Disease
    HPO:Stroke

    Primary Outcomes

    Description: The PAM is a self-reported validated, licensed tool to measure a patient's knowledge, skills and confidence for self-management. The overall score captures the extent to which people feel engaged and confident in taking care of their health condition. It consists of 13 statements rated on a Likert scale according to agreement. Scores are divided into 4 levels, where 1 represents patients who tend to be passive and feel overwhelmed managing their own health, and 4 represents patients who have effectively adopted self-management behaviors. We used a validated licensed Hebrew and version of the PAM supplied by Insignia Health (https://www.insigniahealth.com/products/pam-survey), which holds the copyright to the questionnaire.

    Measure: Patient Activation Measure (PAMĀ®)

    Time: 1 hour

    Description: participants were asked to answer 27 multiple-choice questions regarding status and change in status of mobility, mood (depression, anxiety), tiredness, social support, body weight, physical activity, rehabilitative treatments and disease symptoms

    Measure: Answers to multiple-choice questions

    Time: 1 hour
    12 Impact of COVID-19 on Unplanned Admissions for Acute Cardiovascular and Neurovascular Conditions in France

    The COVID-19 pandemic has had dramatic effects on health systems and on non-COVID health care. Using French inpatient claims data and retrospectively collected clinical data, the investigators will assess the changes in hospital admissions for acute cardiovascular and neurovascular conditions in France during and after the national lockdown.

    NCT04542083
    Conditions
    1. COVID-19
    2. Acute Cardiovascular Condition
    3. Acute Neurovascular Condition
    4. Stroke
    5. Acute Myocardial Infarction
    MeSH:Stroke Myocardial Infarction Infarction Disease
    HPO:Myocardial infarction Stroke

    Primary Outcomes

    Description: Daily number of admissions for acute cardio- and neurivascular conditions in France.

    Measure: Daily number of admissions for acute cardio- and neurivascular conditions in France.

    Time: 1 day

    Secondary Outcomes

    Description: Specific mortality rate.

    Measure: Specific mortality rate.

    Time: 1 day
    13 Depression, Anxiety and SARS-CoV-2 Phobia in Post-stroke Patients During SARS-CoV-2 Pandemic

    Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection has begun, first in Wuhan, China, and then became a pandemic. The first SARS-CoV-2 case in Turkey was reported on March 11, 2020. People older than 65 years old became subject to lock down measures beginning on March 21, while people younger than 20 years old became subject to lock down measures beginning on April 03. A total lock down has been implemented a few times lasting between 3 to 4 days, especially at weekends. Several studies show that mental health problems could occur in public during the SARS-CoV-2 pandemic. Depression and anxiety are a commonly known mental health issue in post-stroke patients. This patient population, who usually have to spend most of their time at home, remained completely at home and socially isolated due to the precautions required by the pandemic. Based on the above research evidence; depression, anxiety and phobia of SARS-CoV-2 may increase in the post stroke patients due to being in risk group and effects of measures taken against SARS-CoV-2 pandemic. Therefore, we aimed to assess the depression, anxiety and SARS-CoV-2 phobia in post stroke patients during SARS-CoV-2 outbreak, and to explore the potential influence factors.

    NCT04560413
    Conditions
    1. SARS-CoV-2
    2. Post-stroke Depression
    3. Anxiety and Fear
    MeSH:Stroke Depression Depressive Disorder Anxiety Disorders
    HPO:Depressivity Stroke

    Primary Outcomes

    Description: The Hospital Anxiety and Depression Scale evaluation includes a total of 14 questions (score range 0-3), which are scored to separately estimate anxiety and depressive status (7 questions each). The individual score for the anxiety and depression subscales may vary from 0 to 21. The aim of this scoring system is not to make an objective diagnosis, but to determine the current presence and tendency to anxiety or depression at the time of diagnosis. A HADS score of 8 to 10 is broadly accepted as indicating mild symptoms, a score between 11-16 suggests moderate anxiety or depression, and a score of 16 or more indicates severe anxiety or depressive symptoms

    Measure: Hospital Anxiety and Depression Scale

    Time: 3 months

    Description: The Covid 19 Phobia Scale is a self-report instrument with a five-point Likert-type scale to assess the levels of SARS-CoV-2 phobia. All items are rated on a 5-point scale from "strongly disagree (1)" to "strongly agree (5)." The scores on the scale can range between 20 and 100 and a higher score indicates a greater phobia in the respected subscales and total scale. In the present study total scale scores ranged from 20 to 100. The scale examines four main factors: psychological, psycho-somatic, economic and social

    Measure: Covid 19 Phobia Scale

    Time: 3 months
    14 COVID-19 Stroke Apical Lung Examination Study - A Multi-centre Prospective Study

    Multi-centre prospective study evaluating computed tomography angiography studies performed for stroke patients as a diagnostic and prognostic imaging biomarker.

    NCT04640428
    Conditions
    1. Covid19
    2. Stroke, Acute
    3. Stroke, Ischemic
    4. Stroke Hemorrhagic
    MeSH:Stroke
    HPO:Stroke

    Primary Outcomes

    Description: Defined by sensitivity, specificity, positive and negative predictive values

    Measure: Accuracy of the computed tomography angiography biomarker relative to the COVID-19 RT-PCR test

    Time: 1 month

    Secondary Outcomes

    Description: Defined by its relationship with 30 day mortality and modified rankin scale following treatment

    Measure: Prognostic value of the computed tomography biomarker

    Time: 1 month

    HPO Nodes


    Reports

    Data processed on December 13, 2020.

    An HTML report was created for each of the unique drugs, MeSH, and HPO terms associated with COVID-19 clinical trials. Each report contains a list of either the drug, the MeSH terms, or the HPO terms. All of the terms in a category are displayed on the left-hand side of the report to enable easy navigation, and the reports contain a list of correlated drugs, MeSH, and HPO terms. Further, all reports contain the details of the clinical trials in which the term is referenced. Every clinical trial report shows the mapped HPO and MeSH terms, which are also hyperlinked. Related HPO terms, with their associated genes, protein mutations, and SNPs are also referenced in the report.

    Drug Reports   MeSH Reports   HPO Reports  

    Interventions

    4,818 reports on interventions/drugs

    MeSH

    706 reports on MeSH terms

    HPO

    306 reports on HPO terms

    All Terms

    Alphabetical index of all Terms

    Google Colab

    Python example via Google Colab Notebook